AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
We haven't written up this one. CNBC has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- STAT+: FDA approves AstraZeneca breast cancer drug statnews.com
- FDA approves new pill for advanced breast cancer guided by blood test medicalxpress.com
- AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes cnbc.com
- New drug shows promise in reducing COPD symptoms in smokers, clinical trials show abcnews.com
